Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 4 percent decrease over losses of $(0.25) per share from the same period last year.
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 4 percent decrease over losses of $(0.25) per share from the same period last year.
Comments